In response to the wildfires that continue to ravage parts of California -- particularly northern California -- the Cystic Fibrosis Foundation has provided the following resources. CF Foundation Compass is standing by to offer support for those impacted by these fires.
In the aftermath of Hurricane Harvey and Hurricane Irma, the Cystic Fibrosis Foundation has provided the following resources. Our Compass team continues to stand by and offer support of those impacted by these storms.
In the aftermath of Hurricane Harvey, our hearts go out to the many people impacted by the storm and flooding, particularly those in our cystic fibrosis community.
New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies.
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.